Enliven Therapeutics, Inc.

ELVN Nasdaq SEC CIK 1672619
Follow Enliven Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$27.7M −37.5% vs same quarter last year
EPS, diluted −$0.36 −12.5% vs same quarter last year
Operating cash flow −$12.6M +5.5% vs same quarter last year
Operating income −$36M −43.6% vs same quarter last year
Net income by quarter
−$23.2M
−$28.5M
−$25.3M
−$20.1M
−$29.7M
−$23.6M
−$32.5M
−$27.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$103.7M
FY24−$89M
FY23−$71.6M
FY22−$37.7M
FY21−$24.7M
FY20−$41.4M
FY19−$23.5M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$70.5M
FY24−$73.2M
FY23−$61.4M
FY22−$32.7M
FY21−$19.3M
FY20−$37.4M
FY19−$22M
FY18-